Dabigatran Etexilate
Dabigatran is an oral anticoagulant medication that works by inhibiting thrombin, a key enzyme in the blood clotting process. It is used to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).-Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. -Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). -Reduction in the risk of recurrence of DVT and PE following initial therapy.
-Atrial Fibrillation: 150 mg twice daily, after 5 to 10 days of initial parenteral anticoagulation. -DVT/PE Treatment: 150 mg twice daily, after 5 to 10 days of initial parenteral anticoagulation. -Dosage adjustments are required based on renal function and patient-specific factors.
-Active pathological bleeding. -Severe hypersensitivity to dabigatran or any excipients. -Concomitant use with other anticoagulants, unless transitioning therapy.
-Renal impairment: Adjust dose based on renal function. -Hepatic impairment: Use with caution in patients with severe hepatic impairment. -Elderly patients: Monitor renal function and bleeding risk. -Spinal/epidural anesthesia or lumbar puncture: Risk of spinal/epidural hematoma.
-Common: Gastrointestinal disturbances (e.g., dyspepsia, abdominal pain, nausea). -Serious: Major bleeding, including gastrointestinal bleeding and intracranial hemorrhage.
-P-glycoprotein inhibitors (e.g., ketoconazole, dronedarone): Increase dabigatran levels. -P-glycoprotein inducers (e.g., rifampin): Decrease dabigatran levels. -Other anticoagulants, antiplatelet drugs, NSAIDs: Increased risk of bleeding.
